Articles with public access mandates - Maurizio ScaltritiLearn more
OverallNIHGovernment of SpainNSFV Foundation, USAEuropean CommissionCancer Research UKSusan G. KomenDoDNIHRGovernment of ItalyHHMIA*StarBreast Cancer Now, UKEPSRCMRCSNSFNSFCDamon Runyon Cancer Research FoundationDOENHMRCDFGHelmholtzBanking Foundation "la Caixa"BBSRCWorldwide Cancer Research, UKResearch Grants Council, Hong KongAIRC Foundation for Cancer Research in ItalyLung Cancer Research Foundation, USAHFSP
Not available anywhere: 1
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
K Jhaveri, MT Chang, D Juric, C Saura, V Gambardella, A Melnyk, ...
Clinical Cancer Research 27 (2), 447-459, 2021
Mandates: US National Institutes of Health
Available somewhere: 108
NTRK fusion-positive cancers and TRK inhibitor therapy
E Cocco, M Scaltriti, A Drilon
Nature reviews Clinical oncology 15 (12), 731-747, 2018
Mandates: US National Institutes of Health
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ...
Cancer cell 19 (1), 58-71, 2011
Mandates: US National Institutes of Health
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
Mandates: US National Institutes of Health
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
Mandates: US National Institutes of Health
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ...
Oncogene 30 (22), 2547-2557, 2011
Mandates: US National Institutes of Health, Government of Spain
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition
YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ...
Cancer discovery 2 (11), 1036-1047, 2012
Mandates: US National Institutes of Health
Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor
D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ...
Nature 518 (7538), 240-244, 2015
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
PJA Eichhorn, M Gili, M Scaltriti, V Serra, M Guzman, W Nijkamp, ...
Cancer research 68 (22), 9221-9230, 2008
Mandates: US National Institutes of Health
Targeted drug delivery strategies for precision medicines
MT Manzari, Y Shamay, H Kiguchi, N Rosen, M Scaltriti, DA Heller
Nature Reviews Materials 6 (4), 351-370, 2021
Mandates: US National Science Foundation, US National Institutes of Health
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ...
Cancer discovery 1 (3), 248-259, 2011
Mandates: US National Institutes of Health
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ...
Journal of Clinical Oncology 36 (24), 2532-2537, 2018
Mandates: US National Institutes of Health
A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion–positive solid tumors
A Drilon, R Nagasubramanian, JF Blake, N Ku, BB Tuch, K Ebata, S Smith, ...
Cancer discovery 7 (9), 963-972, 2017
Mandates: US National Institutes of Health
Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway
Z Li, P Razavi, Q Li, W Toy, B Liu, C Ping, W Hsieh, F Sanchez-Vega, ...
Cancer cell 34 (6), 893-905. e8, 2018
Mandates: US National Institutes of Health
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ...
Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011
Mandates: US National Institutes of Health
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes
EA Mittendorf, Y Wu, M Scaltriti, F Meric-Bernstam, KK Hunt, S Dawood, ...
Clinical Cancer Research 15 (23), 7381-7388, 2009
Mandates: US National Institutes of Health
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C Yang, Z Li, T Bhatt, M Dickler, D Giri, M Scaltriti, J Baselga, N Rosen, ...
Oncogene 36 (16), 2255-2264, 2017
Mandates: US National Institutes of Health, Susan G. Komen
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ...
Science translational medicine 7 (283), 283ra51-283ra51, 2015
Mandates: US National Institutes of Health, European Commission, Government of Spain …
Genetic predictors of response to systemic therapy in esophagogastric cancer
YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, ...
Cancer discovery 8 (1), 49-58, 2018
Mandates: US Department of Defense, US National Institutes of Health
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ...
Science translational medicine 5 (196), 196ra99-196ra99, 2013
Mandates: US National Institutes of Health, Government of Spain
Publication and funding information is determined automatically by a computer program